CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SpectraCure AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SpectraCure AB (publ)
Gasverksgatan 1
Phone: +46 462863770p:+46 462863770 LUND, 222 29  Sweden Ticker: SPECSPEC
Business Summary
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2022Yes----

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board IngemarKihlstrom 67
Chief Executive Officer JohanFolkunger 5/3/2021 5/3/2021
Chief Financial Officer HenrikLjung 64 4/19/2018 4/19/2018
8 additional Officers and Directors records available in full report.

Business Names
Business Name
2OK
SPEC

General Information
Number of Employees: 15 (As of 12/31/2023)
Outstanding Shares: 97,131,608 (As of 12/31/2023)
Shareholders: 17,080
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024